

down.”<sup>1</sup> Health care, like politics, is local. Is it possible that what is cost-effective for one provider or consumer may not be true for another? How much of the problem is “provider” driven as compared with “consumer” driven, in which case the patient has little incentive to consider cost? Since medical egalitarianism does not endorse cost as the arbiter, who will make and enforce the decisions concerning cost? Is the provider free to consider scientific evidence when the trial bar can second-guess the process?

Although scientific advances look toward indi-

vidualized medicine, it appears that cost-accounting exalts the cookbook approach. Since a new system should be tested first on a small scale, perhaps any testing of the new and better health care system should be conducted first on its strongest proponents, the Congress.

Robert C. Kane, M.D.

901 S. Tamiami Trail  
Venice, FL

1. Weinstein MC, Skinner JA. Comparative effectiveness and health care spending — implications for reform. *N Engl J Med* 2010;362:460-5.

## Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing’s Disease

**TO THE EDITOR:** Cushing’s disease, which is caused by an adrenocorticotropin-secreting pituitary adenoma, is associated with increased morbidity and mortality.<sup>1</sup> Currently, there is no effective medical therapy for Cushing’s disease. However, recent studies identified the somatostatin-receptor subtype 5 and dopamine-receptor subtype 2 as potential therapeutic targets in Cushing’s disease.<sup>2</sup>

Pasireotide is a new somatostatin analogue that binds with high affinity to somatostatin-receptor subtypes 1, 2, and 3, and it especially has high-affinity binding to somatostatin-receptor subtype 5.<sup>3</sup> In a recent 15-day pilot study, pasireotide normalized the excretion of urinary free cortisol in 17% of patients with Cushing’s disease.<sup>4</sup> Cabergoline, a dopamine-receptor subtype 2 agonist, can also normalize levels of urinary free cortisol in Cushing’s disease, but this effect is often not maintained during prolonged treatment.<sup>5</sup> Because the majority of adrenocorticotropin-secreting adenomas simultaneously express somatostatin-receptor subtype 5 and dopamine-receptor subtype 2,<sup>2</sup> we hypothesized that pasireotide and dopamine-receptor subtype 2 agonists may have synergistic effects in the treatment of Cushing’s disease. Finally, ketoconazole suppresses cortisol production at the adrenal level through inhibition of steroidogenic enzymes.<sup>1</sup> In a prospective, open-label, multicenter trial, we used a stepwise approach for the medical treatment of Cushing’s disease, with pasireotide as the initial form of treatment and the sequential addition of cabergoline and low-dose ketoconazole.

Seventeen patients with Cushing’s disease (mean age, 45.7 years; 13 women) were included in an 80-day trial with normalization of levels of urinary free cortisol as the main outcome measure. All patients began treatment with 100  $\mu$ g of pasireotide subcutaneously three times daily; this dose was increased to 250  $\mu$ g subcutaneously three times daily at day 15 if the level of urinary free cortisol had not normalized. At day 28, cabergoline was added to pasireotide at a dose of 0.5 mg every other day (this dose was increased to 1.0 mg every other day after 5 days and 1.5 mg every other day after 10 days) if the level of urinary free cortisol remained elevated. If the level of urinary free cortisol had not normalized at day 60, ketoconazole was added at a dose of 200 mg thrice daily.

Pasireotide monotherapy induced sustained normalization of the level of urinary free cortisol in 5 of 17 patients (29%) (Fig. 1A). The addition of cabergoline normalized urinary free cortisol values in an additional 4 of 17 patients (24%). At day 60, a total of 8 of 17 patients (47%) still had elevated urinary free cortisol levels with pasireotide–cabergoline combination therapy, although a trend toward normalization of levels of urinary free cortisol was observed in all but one patient, with a mean ( $\pm$ SE) decrease of  $48\pm 6\%$  in the level of urinary free cortisol. The addition of low-dose ketoconazole induced biochemical remission in six of these eight patients at day 80, increasing the number of patients with a complete response to 88%. Figure 1B shows the effects of 28 days

of pasireotide monotherapy in relation to the severity of hypercortisolism at baseline. In patients with mild hypercortisolism and those with severe hypercortisolism, significant reductions in the level of urinary free cortisol of up to 67% of the baseline value were observed.

Along with the normalization of the level of urinary free cortisol, the clinical features of Cushing's disease improved, including a decrease in body weight ( $-2.4 \pm 0.9$  kg), waist circumference ( $-4.2 \pm 1.3$  cm), systolic blood pressure ( $-12 \pm 4$  mm Hg), and diastolic blood pressure ( $-8 \pm 3$  mm Hg). Adverse events included disturbance of glucose homeostasis (glycated hemoglobin level,  $5.8 \pm 0.2\%$  to  $6.7 \pm 0.3\%$ ;  $P < 0.01$ ) and a decrease in levels of serum type I insulin-like growth factor to below the lower limit of the normal range in 9 of 17 patients.

Thus, stepwise medical therapy for Cushing's disease with the use of three drugs that differentially target somatostatin-receptor subtype 5 and dopamine-receptor subtype 2 receptors in the adrenocorticotropic-secreting adenoma and steroidogenic enzymes in the adrenal cortex resulted in biochemical control in nearly 90% of patients.

Richard A. Feelders, M.D., Ph.D.  
Christiaan de Bruin, M.D., Ph.D.

Erasmus Medical Center  
Rotterdam, the Netherlands  
r.feelders@erasmusmc.nl


Alberto M. Pereira, M.D., Ph.D.  
Johannes A. Romijn, M.D., Ph.D.  
Leiden University Medical Center  
Leiden, the Netherlands

Romana T. Netea-Maier, M.D., Ph.D.  
Ad R. Hermus, M.D., Ph.D.  
Radboud University Nijmegen Medical Center  
Nijmegen, the Netherlands

Pierre M. Zelissen, M.D., Ph.D.  
University Medical Center Utrecht  
Utrecht, the Netherlands

Ramona van Heerebeek  
Frank H. de Jong, Ph.D.  
Aart-Jan van der Lely, M.D., Ph.D.  
Wouter W. de Herder, M.D., Ph.D.  
Leo J. Hofland, Ph.D.  
Steven W. Lamberts, M.D., Ph.D.

Erasmus Medical Center  
Rotterdam, the Netherlands



Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. *Lancet* 2006;367:1605-17.
2. de Bruin C, Pereira AM, Feelders RA, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. *J Clin Endocrinol Metab* 2009;94:1118-24.
3. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. *Mol Cell Endocrinol* 2008;286:69-74.
4. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand and somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. *J Clin Endocrinol Metab* 2009;94:115-22.
5. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. *J Clin Endocrinol Metab* 2009;94:223-30.

## Atypical Femoral Fractures and Bisphosphonate Use

**TO THE EDITOR:** Since 2007, there have been several reports suggesting a potential association between the use of bisphosphonates and the occurrence of subtrochanteric or so-called atypical femoral fracture.<sup>1-4</sup> However, a recent registry-based cross-sectional study did not show a greater frequency of such fractures in patients receiving alendronate.<sup>5</sup> Thus, the association between atypical femoral fractures and bisphosphonate use remains an open issue.

We reviewed 152 femoral fractures (not including hip) that occurred in 152 patients who were admitted to a tertiary center during a 60-month period from June 2003 through May 2008. The mean ( $\pm$ SD) age of the patients was 78 $\pm$ 5 years, and 132 of the patients were women. A senior orthopedic surgeon who was unaware of the patients' baseline characteristics and medication use reviewed the fracture radiographs of every patient in random sequence on two separate occasions (Cohen's  $\kappa=0.8$ ), identifying those fractures that fit the criteria for an atypical fracture (i.e., a lateral transverse or <30-degree oblique fracture line in an area of cortical thickening with a medial uncortical beak), as described previously.<sup>3,4</sup>

Twenty of the 152 fractures were classified as atypical. After unblinding of the database, 17 patients in this group were found to be receiving current oral bisphosphonate treatment. Of these patients, 15 were taking alendronate (mean treatment duration, 5.1 years), and 2 were taking risedronate (mean treatment duration, 3 years). Of the 132 patients whose radiographs did not fulfill the criteria for atypical fracture, 2 patients (1.5%) were taking alendronate, and 1 patient was taking risedronate (0.8%), with mean treatment

durations of 3.5 years and 1 year, respectively. The atypical fracture pattern appeared to be 96.7% specific to patients receiving bisphosphonates.

Several additional risk factors were associated with atypical femur fracture. These included a history of low-energy fracture (odds ratio, 3.2; 95% confidence interval [CI], 2.1 to 17.1;  $P<0.001$ ), the use of glucocorticoid therapy for more than 6 months (odds ratio, 5.2; 95% CI, 1.3 to 31.0;  $P=0.01$ ), active rheumatoid arthritis (odds ratio, 16.5; 95% CI, 1.4 to 142.3;  $P<0.001$ ), and a level of serum 25-hydroxyvitamin D of less than 16 ng per milliliter (40 nmol per liter) (odds ratio, 3.5; 95% CI, 1.7 to 18.7;  $P<0.001$ ).

Although there is an association between atypical subtrochanteric femur fracture and oral bisphosphonate use, clinicians should remember that bisphosphonates significantly reduce the risk of fragility fractures in patients with osteoporosis and that overall the antifracture effects of bisphosphonates far outweigh their potential risks.

Christian M. Girgis, M.B., B.S.  
Doron Sher, M.B., B.S., F.R.A.C.S.  
Markus J. Seibel, M.D., Ph.D.

University of Sydney  
Sydney, NSW, Australia  
cgirgis@usyd.edu.au

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

1. Lee P, van der Wall H, Seibel MJ. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. *J Endocrinol Invest* 2007;30:590-7.
2. Lee P, Seibel MJ. More on atypical fractures of the femoral diaphysis. *N Engl J Med* 2008;359:317.
3. Neviaser AS, Lane JM, Lenart BA, Edober-Osula F, Lorch